论文部分内容阅读
目的:分析参附注射液治疗缺血性心肌病心衰的临床疗效研究及安全性。方法:选择2012年3月~2014年7月期间于我院行缺血性心肌病心衰治疗的患者64例为研究对象,采用随机数字表法分为观察组和对照组各32例,对照组采用常规治疗,观察组在对照组的基础上加用参附注射液治疗,比较两组患者治疗效果、心功能、并发症的发生情况。结果:观察组有效率(93.75%)明显高于对照组(75.00%);左心室舒张末期内径(LVDD)、左心室收缩末期内径(LVSD)明显低于对照组、左心室射血分数(LVEF)明显高于对照组;并发症发生率(6.25%)明显低于对照组(21.88%)。结论:参附注射液有助于改善缺血性心肌病心衰患者的心功能,降低不良反应,提高治疗效果。
Objective: To analyze the clinical efficacy and safety of Shenfu Injection in the treatment of heart failure of ischemic cardiomyopathy. Methods: Sixty-four patients with ischemic cardiomyopathy and heart failure treated in our hospital from March 2012 to July 2014 were selected as the study subjects. The patients were divided into observation group (32 cases) and control group (32 cases) by random number table The patients in the observation group were treated with Shenfu injection on the basis of the control group, and the treatment effect, cardiac function and complications of the two groups were compared. Results: The effective rate (93.75%) in the observation group was significantly higher than that in the control group (75.00%). The left ventricular end diastolic diameter (LVDD) and left ventricular end systolic diameter (LVSD) were significantly lower than those in the control group ) Was significantly higher than the control group; the incidence of complications (6.25%) was significantly lower than that of the control group (21.88%). Conclusion: Shenfu injection can improve heart function, reduce adverse reactions and improve the therapeutic effect in patients with heart failure of ischemic cardiomyopathy.